These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 11207782

  • 21. Elevation of brain gamma-aminobutyric acid levels is associated with vigabatrin-associated brain abnormalities on magnetic resonance imaging.
    Ikeda A, Tomiyasu M, Yamamoto A, Tsuyusaki Y, Kawai Y, Tanabe M, Tsuji M, Iai M, Aida N, Goto T.
    Epilepsy Res; 2022 Mar; 181():106881. PubMed ID: 35183975
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose.
    Petroff OA, Rothman DL, Behar KL, Mattson RH.
    Neurology; 1996 May; 46(5):1459-63. PubMed ID: 8628502
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Nuclear magnetic resonance detection of increased cortical GABA in vigabatrin-treated rats in vivo.
    Preece NE, Jackson GD, Houseman JA, Duncan JS, Williams SR.
    Epilepsia; 1994 May; 35(2):431-6. PubMed ID: 8156969
    [Abstract] [Full Text] [Related]

  • 27. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.
    Petroff OA, Rothman DL.
    Mol Neurobiol; 1998 Feb; 16(1):97-121. PubMed ID: 9554704
    [Abstract] [Full Text] [Related]

  • 28. Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration.
    Świąder MJ, Świąder K, Zakrocka I, Krzyżanowski M, Wróbel A, Łuszczki JJ, Czuczwar SJ.
    Pharmacol Rep; 2020 Apr; 72(2):322-330. PubMed ID: 32048251
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy.
    Dodrill CB, Arnett JL, Sommerville KW, Sussman NM.
    Epilepsia; 1995 Feb; 36(2):164-73. PubMed ID: 7821274
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Cerebrospinal fluid GABA and seizure control with vigabatrin.
    Riekkinen PJ, Ylinen A, Halonen T, Sivenius J, Pitkanen A.
    Br J Clin Pharmacol; 1989 Feb; 27 Suppl 1(Suppl 1):87S-94S. PubMed ID: 2757914
    [Abstract] [Full Text] [Related]

  • 37. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study.
    Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T.
    Ther Drug Monit; 2003 Aug; 25(4):457-62. PubMed ID: 12883229
    [Abstract] [Full Text] [Related]

  • 38. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group.
    Mauguière F, Chauvel P, Dewailly J, Dousse N.
    Epilepsia; 1997 Mar; 38(3):301-8. PubMed ID: 9070592
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Vigabatrin.
    Mumford JP, Cannon DJ.
    Epilepsia; 1994 Mar; 35 Suppl 5():S25-8. PubMed ID: 8039466
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.